Many Invitae Corporation(NVTA) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Upgraded by The Benchmark Company on Feb 14, 2017 to Buy, Raises Price Target to $ 11 from a previous price target of $8.50 .
Company has reported several Insider transactions to the SEC, on Nov 22, 2016, Randal W Scott (CEO) purchased 66,666 shares at 6.00 per share price.On Nov 21, 2016, Geoffrey Crouse (director) purchased 15,000 shares at 6.25 per share price.On Nov 21, 2016, Eric Aguiar (director) purchased 10,000 shares at 6.28 per share price.
InVitae Corp Last issued its quarterly earnings results on Feb 13, 2017. The company reported $-0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $-0.72. The company had revenue of $9.20 million for the quarter, compared to analysts expectations of $8.82 million. The companys revenue was up 187.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.76 EPS.
Invitae Corporation (NYSE:NVTA) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.67 by 3 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.
Invitae Corporation (NYSE:NVTA): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $13 in Invitae Corporation (NYSE:NVTA). However, the stock price could fluctuate by $ 1.41 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $14 price target with the lower price estimate is calculated at $12
Invitae Corporation (NYSE:NVTA) rose 7.21% or 0.66 points on Tuesday and made its way into the gainers of the day. After trading began at $10.59 the stock was seen hitting $10.65 as a peak level and $9.45 as the lowest level. The stock ended up at $9.82. The daily volume was measured at 944,128 shares. The 52-week high of the share price is $11.85 and the 52-week low is $5.76. The company has a market cap of $404 million.
Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.